TherapeuticsMD (TXMD) EBITDA Margin (2011 - 2026)
TherapeuticsMD (TXMD) reported EBITDA Margin of 99.86% for Q1 2026, up 22609.0% on a YoY basis from N/an in Q1 2025, and up 42.54% quarter-over-quarter from 173.8% in Q4 2025.
TherapeuticsMD (TXMD) EBITDA Margin (2011 - 2026) Analysis & Trends
TherapeuticsMD has reported EBITDA Margin for 16 years, with the latest figure at 99.86% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 22609.0% year-over-year to 99.86%; the trailing twelve-month figure through Mar 2026 stood at 114.29% (up 20380.0% YoY), and the FY2025 full-year result was 145.27%, up 20181.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 99.86%, up from 173.8% in the prior quarter.
- The five-year high for EBITDA Margin was 32264.66% in Q2 2022, with the low at 8182.2% in Q3 2022.
- Historically, EBITDA Margin has averaged 384.12% across 5 years, with a median of 207.31% in 2024.
- Annual changes were most pronounced in 2022 — EBITDA Margin jumped 3245009 bps — and 2023, when it tumbled 3281706 bps.
- TherapeuticsMD's EBITDA Margin stood at 113.32% in 2022, then tumbled by 255 bps to 175.9% in 2023, then soared by 44 bps to 97.75% in 2024, then tumbled by 78 bps to 173.8% in 2025, then surged by 43 bps to 99.86% in 2026.
- The last three EBITDA Margin figures came in at 99.86% (Q1 2026), 173.8% (Q4 2025), and 109.95% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | TherapeuticsMD | 21,180.42 | -8.40 Mn | - | -99.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -99.86% |
| Dec 31, 2025 | -173.80% |
| Sep 30, 2025 | -109.95% |
| Jun 30, 2025 | -73.00% |
| Mar 31, 2025 | -325.95% |
| Dec 31, 2024 | -97.75% |
| Sep 30, 2024 | -207.31% |
| Jun 30, 2024 | -1,191.88% |
| Mar 31, 2024 | -364.86% |
| Dec 31, 2023 | -175.90% |
| Sep 30, 2023 | -6,373.58% |
| Jun 30, 2023 | -552.40% |
| Mar 31, 2023 | -866.11% |
| Dec 31, 2022 | 113.32% |
| Sep 30, 2022 | -8,182.20% |
| Jun 30, 2022 | 32,264.66% |
| Mar 31, 2022 | -7,053.38% |
| Dec 31, 2021 | -230.00% |
| Sep 30, 2021 | -186.65% |
| Jun 30, 2021 | -185.44% |